로딩 중…
지수 로딩 중…
Arbutus Biopharma Corporation
ABUS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$4.36+0.46%
2026-08-03
Financials
Valuation Metrics
Arbutus Biopharma Corporation's Market Cap is $861M. At end of 2025 it was $922M. Ranked #2563 of 3,111 in US market (top 82%), #1068 of 1,445 on NASDAQ (top 74%), #199 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $861M | US#2,563/3,111 Sec#199/269 |
| Revenue | $191M | US#2,697/3,111 Sec#116/269 |
| Net Income | $161M | US#1,374/3,111 Sec#49/269 |
| Total Assets | $277M | US#2,932/3,111 Sec#226/269 |
| Net Assets | $260M | US#2,628/3,111 Sec#175/269 |
| Value | ||
| P/E | 5.36x | US#56/3,111 Sec#7/269 |
| P/B | 3.31x | US#1,808/3,111 Sec#102/269 |
| P/S | 4.50x | US#2,193/3,111 Sec#72/269 |
| EV/EBITDA | 5.21x | US#170/3,111 Sec#11/269 |
| FCF Yield | -3.99% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | 61.77% | US#89/3,111 Sec#10/269 |
| ROA | 57.99% | US#4/3,111 Sec#2/269 |
| Op. Margin | 80.79% | US#19/3,111 Sec#1/269 |
| Revenue Growth | 10054.54% | US#10/3,111 Sec#3/269 |
| Financial Health | ||
| Debt Ratio | 6.53% | US#67/3,111 Sec#32/269 |
| Total Debt | $631000.00 | US#2,973/3,111 Sec#257/269 |
| FCF | $-34M | US#2,437/3,111 Sec#106/269 |
| Cash | $24M | US#2,841/3,111 Sec#260/269 |
| Current Ratio | 54.26x | US#49/3,111 Sec#2/269 |
| Net Debt/EBITDA | -0.14x | US#558/3,111 Sec#31/269 |
| Performance | ||
| 1Y Return | 33.33% | US#1,098/3,111 Sec#143/269 |
| 1M Return | -10.47% | US#2,380/3,111 Sec#169/269 |
| From 52W High | -18.96% | US#1,617/3,111 Sec#108/269 |
| 1Y MDD | -25.86% | US#1,085/3,111 Sec#60/269 |
| Trading | ||
| Volume | 1,389,791 shares | US#1,307/3,111 Sec#124/269 |
| Trading Value | $6M | US#2,633/3,111 Sec#220/269 |
| Per Share | ||
| EPS | $-0.16 | US—/3,111 Sec—/269 |
| BPS | $0.40 | US#2,697/3,111 Sec#225/269 |